FDA expands use of Actemra to include polyarticular JIA

Genentech received approval from the Food and Drug Administration to market Actemra, or tocilizumab, for children age 2 and older with active polyarticular juvenile idiopathic arthritis. The drug, a humanized interleukin-6 receptor antagonist, can be given alone or with methotrexate. The approval was based on data from a late-stage trial showing that the drug improved symptoms in children with the condition.

View Full Article in:

Medscape (free registration) · BioPharm International online

Published in Brief:

SmartBrief Job Listings for Education

Job Title Company Location
K-12 Teachers Needed at Int’l Schools
The International Educator
Multiple Locations
Professional Development (PD) Staff Trainer
NWEA
Multiple Locations, SL_Multiple Locations
Professional Development (PD) Consultant
NWEA
Chicago, IL
Sales Manager (Education K-12)
ALL Management Corporation
Los Angleles, CA
Advocate Marketing Manager
GiftedandTalented.com
San Mateo, CA